BERA ENT in detaill

Reading File

BERA (Brainstem Evoked Response Audiometry) is a key electrophysiological test in ENT used to assess the auditory pathway from cochlea to brainstem. Let me search the medical library for detailed coverage.

Searching sources...

Finding Sources

Good. I have three strong sources. Let me read them in parallel now.

Reading File

Excellent content. Let me now read more from Cummings (the most detailed ABR section) and from Scott-Brown's on clinical applications.

Reading File

I now have extensive, high-quality information. Let me also fetch the ABR waveform image and check clinical applications/neonatal screening from KJ Lee, then compile the full answer.

Finding Sources

Loading Image

I have more than enough detailed content from three authoritative ENT textbooks. Here is the comprehensive answer:

BERA (Brainstem Evoked Response Audiometry) - Detailed Notes for ENT

BERA is synonymous with ABR (Auditory Brainstem Response). It is an electrophysiological test that records electrical activity of the auditory pathway from the cochlea to the brainstem in response to auditory stimuli.

1. Definition

BERA records surface-averaged electrical potentials generated by sequential activation of the auditory nerve and brainstem nuclei following acoustic stimulation. Because the brainstem is relatively impervious to sedatives, anaesthetics, and CNS depressants, it is an objective, reliable test in uncooperative or sleeping patients.

Cummings Otolaryngology, p. 2577

2. Historical Background

First described by Jewett and Williston who identified a complex occurring under 10 ms post-onset of an auditory stimulus, comprising five distinct potentials (waves I-V).
Scott-Brown's Otorhinolaryngology, p. 694

3. Basis / Principle

An auditory click stimulus causes synchronized activation of thousands of auditory nerve fibres. The summed electrical activity is recorded from scalp electrodes, averaged across 1000-3000 sweeps, and produces a characteristic waveform with five positive peaks (waves I-V) within 10 ms.

4. Wave Generators ("EECOL" Mnemonic)

Wave	Generator	Approximate Normal Absolute Latency
I	Distal (peripheral) end of 8th nerve (cochlear nerve)	~1.5 ms
II	Proximal end of 8th nerve (near porus acusticus)	~2.5 ms
III	Cochlear nucleus (ventral acoustic stria)	~3.5 ms
IV	Superior olivary complex + lateral lemniscus	~4.5 ms
V	Lateral lemniscus (+ possibly inferior colliculus)	~5.5 ms

Mnemonic: EECOL - Eighth nerve (distal), Eighth nerve (proximal), Cochlear nucleus, Olivary complex, Lateral lemniscus

KJ Lee's Essential Otolaryngology, p. 1211
Cummings Otolaryngology, p. 2578
Scott-Brown's Otorhinolaryngology, p. 694

Note: Wave V is the most robust and reliable wave. Waves IV and V often fuse into a complex (IV/V complex).

5. Technique / Recording Parameters

Electrodes

Non-inverting (active): High forehead below the hairline or vertex (Cz)
Inverting (reference): Medial surface of the ipsilateral earlobe (Ai) - emphasises Wave I
Contralateral inverting: Medial surface of the contralateral earlobe - emphasises separation of waves IV and V
Ground: Centre of the forehead

This gives a 2-channel montage.

Stimulus

Click stimulus: 100 microsecond rectangular pulse - most common for retrocochlear testing
Tone burst/pip: Frequency-specific (used for threshold estimation, e.g. 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz)
Stimulus rate: 20-30 clicks/second (non-integer rate such as 17.7/sec to avoid periodic noise)
Fast-rate ABR uses 77.7 clicks/second
Polarity: Constant or alternating

Signal Averaging

1000-3000 sweeps are averaged to extract the evoked potential from background noise
Each condition is replicated (acquired twice or three times) to confirm reliability

Filtering

High-pass filter: 100 Hz
Low-pass filter: 1000-3000 Hz
For 500 Hz tone burst: lower high-pass to ~30 Hz
Notch filter (60 Hz) only used sparingly when electrical artefact cannot be eliminated

Recording Window

10-15 ms post-stimulus onset - to capture all five waves
Scott-Brown's Otorhinolaryngology, p. 694-695
Cummings Otolaryngology, p. 2577-2578

6. Normal Interpeak Latency Values

Interval	Normal Limit
Wave I absolute latency	~1.5 ms
Wave V absolute latency	< 6.2 ms
I-III interwave interval	< 2.5 ms (KJ Lee: 2.3 ms)
III-V interwave interval	< 2.4 ms (KJ Lee: 2.1 ms)
I-V interwave interval	< 4.4 ms
Inter-ear latency difference (ILD) of wave V	< 0.5 ms
Fast-rate latency shift	< 1.0 ms

KJ Lee's Essential Otolaryngology, p. 1211
Scott-Brown's Otorhinolaryngology, Table 52.1, p. 695

7. Clinical Indications

A. Neonatal / Paediatric Hearing Screening

Brainstem function is identifiable on ABR at approximately 28 weeks gestational age - waves I, III and V appear.
ABR "maturity" (adult-like latencies) is not reached until approximately 18 months after birth - neonatal latencies are prolonged compared to adults.
BERA is the gold standard test for Universal Newborn Hearing Screening (UNHS) when OAE refer.
It is the first-choice test for infants in the at-risk registry: birth asphyxia, ototoxic drugs, NICU, family history, congenital infections, craniofacial anomalies, hyperbilirubinaemia.
KJ Lee's Essential Otolaryngology, p. 1210-1211

B. Threshold Estimation

Used in children, neonates, and malingerers who cannot or will not cooperate with behavioural audiometry.
Tone-burst BERA gives frequency-specific thresholds at 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz.
ABR threshold correlates well with behavioural auditory threshold.

C. Retrocochlear Lesion Detection - Acoustic Neuroma (Vestibular Schwannoma)

The primary neurodiagnostic indication.
An acoustic neuroma delays conduction time along the cochlear nerve, prolonging absolute and interwave latencies.
Diagnostic sensitivity of ABR for acoustic neuroma:
- I-III interval: ~90% sensitivity, 100% specificity
- I-V interval: ~75% sensitivity
- III-V interval: ~45% sensitivity
- Inter-ear latency difference (ILD): >90% sensitivity and specificity
Scott-Brown's Otorhinolaryngology, p. 695

D. Neurological / Brainstem Disease

Multiple sclerosis (demyelination prolongs interwave latencies)
Brainstem tumours, haemorrhage, infarction
Coma and brain death evaluation

E. Intraoperative Monitoring

Used during posterior fossa surgery (e.g. acoustic neuroma resection, microvascular decompression) to monitor auditory nerve integrity in real time.
Decline or loss of wave V amplitude or marked latency prolongation warns the surgeon of potential cochlear nerve injury.
Cummings Otolaryngology, p. 2578-2579

8. Interpretation - Patterns of Abnormality

Retrocochlear Lesion (e.g. Acoustic Neuroma)

Suspect if ANY of the following:

Interpeak latency I-V > 4.4 ms
Interaural wave V latency difference > 0.2 ms (KJ Lee) or > 0.5 ms (Scott-Brown normative table)
III-V interval > 2.4 ms
Absent wave I with present wave V (suggests peripheral cochlear nerve involvement)
Absent or poorly formed ABR waveform
Fast-rate latency shift > 1.0 ms

Cochlear (Sensory) Hearing Loss

All absolute latencies are prolonged equally (latency-intensity shift)
Interwave intervals remain normal
ABR threshold elevated corresponding to degree of hearing loss

Auditory Neuropathy / Dyssynchrony (AN/AD)

Normal OAEs (outer hair cells intact)
Absent or severely abnormal ABR (lack of neural synchrony)
This dissociation is the hallmark finding.

Conductive Hearing Loss

All wave latencies shifted to the right (prolonged) by the amount of conductive loss
Interwave intervals remain normal
ABR improves with bone conduction stimulation

Normal ABR

All five waves (I-V) present with normal absolute and interwave latencies
Symmetrical bilaterally

9. BERA vs. OAE - Comparison

Feature	BERA/ABR	OAE
Tests	Auditory nerve + brainstem	Outer hair cells (cochlea)
Result	Objective threshold + neural path	Cochlear function only
Sedation needed	Often (especially neonates)	No
Frequency specific	Yes (tone burst)	Yes
Screening cost	Higher	Lower (preferred 1st screen)
Auditory neuropathy	Abnormal	Normal

10. Advantages of BERA

Objective - does not require patient cooperation or response
Unaffected by sedation/anaesthesia - brainstem is impervious to CNS depressants
Frequency-specific thresholds possible with tone bursts
Neurodiagnostic - detects retrocochlear and brainstem pathology
Intraoperative monitoring capability
Useful from neonatal period onwards

11. Limitations

Time-consuming compared to OAE
Requires quiet, often sedated patient in infants
A good response requires synchronous neural firing - absent in auditory neuropathy, but this is also diagnostically useful
Does not test cortical/central auditory processing (needs AMLR or P300 for that)
Cannot assess hearing above the brainstem level

12. Aural Atresia and BERA

BERA is part of the audiological workup in congenital aural atresia at birth (along with OAE) with formal audiometry at 18 months to plan management.

KJ Lee's Essential Otolaryngology

Summary Table

Feature	Details
Also called	ABR, BAER, BAEP
Stimulus	Click (100 µs) or tone burst
Number of sweeps	1000-3000
Recording window	10-15 ms
Waves	I-V (5 peaks)
Most reliable wave	Wave V
Normal I-V interval	< 4.4 ms
Normal wave V latency	< 6.2 ms
Key diagnostic use	Acoustic neuroma, neonatal screening
Intraoperative use	Yes
Affected by anaesthesia	No

Sources:

Cummings Otolaryngology Head and Neck Surgery, pp. 2577-2579
Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol 2, pp. 694-695
KJ Lee's Essential Otolaryngology, p. 1211

Retinoblastoma

Reading File

Retinoblastoma is the most common intraocular malignancy of childhood. Let me search the medical library for detailed coverage.

Searching sources...

Finding Sources

Excellent. Kanski's Clinical Ophthalmology and Robbins Pathology are the best sources. Let me read all key sections in parallel.

Reading File

Excellent data from Kanski's and Thompson genetics. Let me read more of Kanski's for clinical features, staging, and treatment, and also fetch the key images.

Reading File

Now let me read more from Kanski's for clinical features, staging (International Classification), and treatment details, and fetch the key clinical images.

Reading File

Loading Image

I now have comprehensive data from Kanski's Ophthalmology, Robbins Pathology, and Thompson Genetics. Let me read the remaining treatment section and fetch one more clinical image.

Reading File

Loading Image

I now have comprehensive content. Let me fetch the Flexner-Wintersteiner rosette histology image and the leukocoria image from Kanski's, then compile the full answer.

Reading File

Loading Image

I now have all the information needed for a comprehensive answer. Here it is:

Retinoblastoma - Detailed Notes

1. Overview

Retinoblastoma is the most common primary intraocular malignancy of childhood, occurring in up to 1:18,000 live births. It accounts for approximately 3% of all childhood cancers. After uveal melanoma, it is the second most common malignant intra-ocular tumour overall. Survival rates exceed 95% in specialised centres, but are much lower in the developing world.

Kanski's Clinical Ophthalmology, p. 891

2. Genetics - The "Two-Hit Hypothesis" (Knudson)

Retinoblastoma is the prototype of a tumour suppressor gene (TSG) disease. The responsible gene is RB1 on chromosome 13q14.

Two-Hit Model

First hit: mutation in one RB1 allele
Second hit: somatic mutation in the second allele → loss of both copies → malignant transformation

Child with leukocoria (white reflex) in the left eye - retinoblastoma

Retinoblastoma presenting as leukocoria (white reflex) in the left eye of a young child (Thompson & Thompson Genetics)

Hereditary vs. Sporadic

Feature	Hereditary (Germline)	Sporadic (Somatic)
Proportion	40%	60%
First hit	Germline (all cells)	Somatic (single retinal cell)
Laterality	Usually bilateral, multifocal	Unilateral, unifocal
Age of onset	Earlier (< 1 year)	Later (~2 years)
Inheritance	Autosomal dominant (apparent)	Not inherited
Second malignancies	Yes (osteosarcoma, etc.)	No
Penetrance	>90% but not complete	-

Over 900 different RB1 mutations have been reported.
In a small proportion of sporadic cases, NMYC proto-oncogene amplification is observed instead of RB1 mutation.
Thompson & Thompson Genetics, p. 370; Kanski's, p. 891; Robbins Pathology, p. 1924

Second Malignancies in Heritable Retinoblastoma

Pinealoblastoma ("trilateral retinoblastoma") - up to 10%, usually before age 5
Osteosarcoma
Soft tissue sarcoma
Melanoma
Overall risk ~6%, but increases 5-fold if external beam radiotherapy was used
Kanski's Clinical Ophthalmology, p. 891

3. Pathology

Gross Appearance

Growth patterns:

Endophytic - grows into the vitreous; seeding of tumour cells throughout the eye
Exophytic - grows into the subretinal space; causes retinal detachment
Mixed
Diffuse infiltrating - rare pattern; flat infiltration of retina, often older children, mimics uveitis

Optic nerve invasion may occur with spread along the subarachnoid space to the brain. Metastases go to regional lymph nodes, lung, brain, and bone.

Histology

Small, round, basophilic cells (retinoblasts) with large hyperchromatic nuclei and scanty cytoplasm
Many tumours are undifferentiated
Differentiation is shown by rosette formation:

Rosette Type	Significance
Flexner-Wintersteiner rosettes	Most characteristic; show photoreceptor differentiation; columnar cells around a central lumen
Homer-Wright rosettes	Less specific; pseudorosettes; no central lumen
Fleurettes	Most differentiated; represent photoreceptor-like elements

Histology of retinoblastoma - small basophilic cells with large hyperchromatic nuclei, H&E stain

Histology: Dense clusters of small basophilic cells with large hyperchromatic nuclei - undifferentiated retinoblastoma (Robbins Pathology)

Focal zones of dystrophic calcification are characteristic
Viable tumour cells encircle blood vessels; zones of necrosis in relatively avascular areas
Degree of differentiation does not correlate with prognosis
Robbins & Cotran Pathologic Basis of Disease, p. 1924

Gross pathology of the globe showing large dark tumour mass filling the vitreous cavity with retinal detachment

Gross section of enucleated globe showing the dark tumour mass filling most of the vitreous cavity (Kanski's Ophthalmology)

4. Clinical Features

Age of Presentation

Bilateral cases: within the first year of life
Unilateral cases: around 2 years of age

Presenting Signs (in order of frequency)

Feature	Frequency
Leukocoria (white pupillary reflex)	~60% - most common
Strabismus	~20% - second most common
Painful red eye (neovascular glaucoma)	Less common
Heterochromia iridis	Rare
Orbital cellulitis appearance	Rare (masquerade)
Proptosis	Advanced disease
Reduced vision	May be noted by parents

TIP: Retinoblastoma must be excluded in any young child with leukocoria or a squint. Fundus examination is mandatory in ALL cases of childhood squint. - Kanski's, p. 892

Leukocoria may first be noticed in family photographs when flash photography causes a white rather than red reflex in the affected eye.

5. International Classification of Retinoblastoma (IIRC)

Group	Description
A	Small intraretinal tumours (<3 mm) away from foveola and disc
B	Tumours >3 mm, or macular/juxtapapillary location, or with subretinal fluid
C	Tumour with focal subretinal or vitreous seeding within 3 mm of tumour
D	Tumour with diffuse subretinal or vitreous seeding >3 mm from tumour
E	Extensive tumour occupying >50% of globe ± neovascular glaucoma, haemorrhage, optic nerve/anterior chamber extension

Kanski's Clinical Ophthalmology, p. 892

6. Investigations

Examination Under Anaesthesia (EUA)

General examination for congenital abnormalities
Tonometry
Corneal diameter measurement
Anterior chamber exam (hand-held slit lamp)
Wide-field ophthalmoscopy with documentation (colour drawings or photography)
Cycloplegic refraction

Imaging

Ultrasound (B-scan): First-line; assesses tumour size, detects calcification (characteristic), excludes differential diagnoses (e.g. Coats disease)
CT scan: Also detects calcification but delivers radiation; avoided by many practitioners especially in heritable cases due to second malignancy risk
MRI: Does not detect calcification; useful for optic nerve evaluation, extraocular extension, pinealoblastoma detection, and differentiating from simulating conditions
Plain X-ray: Detects calcification in resource-poor settings

Systemic Assessment

Physical examination
MRI of orbit and skull (in high-risk cases)
If metastases suspected: bone scan, bone marrow aspiration, lumbar puncture

Genetic Studies

Tumour tissue + blood samples from patient and relatives
RB1 mutation detection approaches 95% sensitivity

7. Differential Diagnosis of Leukocoria

Condition	Key Differentiating Feature
Coats disease	Telangiectatic retinal vessels; no calcification on US
Persistent foetal vasculature (PHPV)	Microphthalmia; no calcification
Toxocara	History of exposure to dogs; unilateral
Cataract	Lens opacity on slit-lamp
ROP	Premature infant, bilateral
Norrie disease	X-linked, bilateral
Retinal astrocytic hamartoma	Associated with tuberous sclerosis

8. Screening

Germline mutations are transmitted with autosomal dominant inheritance (50% transmission; ~40% offspring affected due to incomplete penetrance)
Siblings at risk should be screened by:
- Prenatal ultrasonography
- Ophthalmoscopy soon after birth
- Regular examinations until age 5-7 years
With effective screening and early treatment: final visual acuity of 6/6 to 6/12 achievable in up to 90%
Risk to siblings:
- 2% if both parents are healthy
- 40% if one parent is affected
Kanski's Clinical Ophthalmology, p. 892

9. Treatment

Treatment is highly individualised and requires a collaborative team (ophthalmologist, paediatric oncologist, ocular pathologist, geneticist, allied health).

Chemotherapy (Mainstay)

1. Intravenous (systemic) chemotherapy

CEV regimen: Carboplatin + Etoposide + Vincristine
3-6 cycles depending on group
Used for chemo-reduction to shrink tumour before focal consolidation

2. Selective Ophthalmic Artery Infusion (Intra-arterial chemotherapy, IAC)

Catheter via femoral artery → ophthalmic artery
Drugs: Melphalan or topotecan
Significantly better globe salvage vs. IV chemotherapy, especially for Group D eyes
Risks: chorioretinal ischaemia, visual loss
Kanski's, p. 894

3. Intravitreal chemotherapy

Intravitreal melphalan for vitreous seeding
Small risk of extraocular dissemination

Focal/Local Consolidation

Modality	Indication
Transpupillary thermotherapy (TTT)	Focal consolidation post-chemo; direct treatment of small tumours
Cryotherapy	Pre-equatorial tumours; triple freeze-thaw technique; no deep invasion or vitreous seeding
Brachytherapy (radioactive plaque)	Anterior tumour without vitreous seeding; resistance to chemotherapy

External Beam Radiotherapy (EBRT)

Avoided especially in heritable retinoblastoma due to 5-fold increased risk of second malignancy within the irradiated field
Reserved for residual/relapsed disease after other treatments
Complications: cataract, radiation neuropathy, radiation retinopathy, orbital hypoplasia

Enucleation (Surgical Removal of the Eye)

Indicated when:

Neovascular glaucoma
Anterior chamber infiltration
Optic nerve invasion
Tumour occupies >50% of vitreous volume (Group E)
Failure of chemo-reduction
Diffuse retinoblastoma
Technique: minimal manipulation; optic nerve section must be ≥10 mm from the globe
Kanski's Clinical Ophthalmology, p. 894

10. Prognosis and Spread

Favourable Factors

Small tumour (Groups A-B)
No optic nerve involvement
No choroidal invasion
Early diagnosis and treatment

Adverse Prognostic Factors

Extraocular extension
Optic nerve invasion (especially beyond the lamina cribrosa)
Massive choroidal invasion
Anterior chamber involvement

Pattern of Spread

Direct: along optic nerve → subarachnoid space → brain
Haematogenous: to bone, bone marrow
Lymphatic: to regional lymph nodes
Metastases tend to go to brain and bone marrow; seldom to the lungs
Robbins & Cotran Pathologic Basis of Disease, p. 1924

Survival

95% in specialised centres (developed world)
Much lower in developing world due to late presentation

11. Key Points Summary

Feature	Detail
Most common intraocular tumour	In children
Gene	RB1 on chromosome 13q14
Inheritance	Autosomal dominant (40% hereditary)
Bilaterality	Hereditary = bilateral; Sporadic = unilateral
Most common presentation	Leukocoria (60%)
Second most common sign	Strabismus (20%)
Characteristic histology	Flexner-Wintersteiner rosettes
Characteristic imaging finding	Calcification on B-scan/CT
Mainstay of treatment	Chemotherapy (CEV; intra-arterial)
Avoid	External beam radiotherapy (hereditary cases)
Enucleation indication	Group E, failed chemo, optic nerve invasion
Trilateral retinoblastoma	+ Pinealoblastoma (hereditary)
Prototype of	Tumour suppressor gene / two-hit hypothesis

Sources:

Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed., pp. 891-895
Robbins & Cotran Pathologic Basis of Disease, pp. 1924-1925
Thompson & Thompson Genetics and Genomics in Medicine, 9th ed., pp. 369-371
Robbins & Kumar Basic Pathology, p. 146

This is a shared conversation. Sign in to Orris to start your own chat.